
医学资讯AficamtenMAPLE-HCM
超越β受体阻滞剂:Aficamten重塑梗阻性肥厚型心肌病的一线治疗
By MedXY|2025年12月26日
MAPLE-HCM试验表明,Aficamten单药治疗在多个疾病领域为有症状的梗阻性肥厚型心肌病患者提供了优于传统一线治疗美托洛尔的快速、全面的临床益处。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.